Antisense News and Research

RSS

Antisense is the non-coding strand in double-stranded DNA. The antisense strand serves as the template for mRNA synthesis.

Study reveals novel approach to promote efficient uptake of ASOs into cancer cells

Antisense oligonucleotides (ASOs) are next-generation drugs that can treat disease by blocking the transfer of harmful messages from our genes.

16 Apr 2024

Smartphone app shows promise in detecting early signs of frontotemporal dementia

UCSF-led research shows smartphone cognitive testing is comparable to gold-standard methods; may detect FTD in gene carriers before symptoms start.

1 Apr 2024

Targeting a non-encoding stretch of RNA may shrink pediatric brain tumors in mice

Targeting a non-encoding stretch of RNA may help shrink tumors caused by an aggressive type of brain cancer in children, according to new research in mice reported March 8 in Cell Reports by Johns Hopkins Kimmel Cancer Center investigators.

13 Mar 2024

UCSF scientists discover less invasive prenatal treatment for Angelman syndrome

In a discovery that opens the door to a less invasive way of treating some serious disorders before birth, UC San Francisco scientists have found that delivering medicine through amniotic fluid is as effective as delivering it to the fetal brain via cerebrospinal fluid.

4 Mar 2024

Yale School of Medicine secures $575,000 grant for Long COVID research

Yale School of Medicine and its Center for Infection & Immunity (CII) are receiving a $575,000 grant from PolyBio Research Foundation to fund Long COVID research.

23 Feb 2024

Combo of targeted and immunotherapy may boost NSCLC treatment by overcoming immune resistance and enhancing anti-tumor activity

Researchers evaluated rational combination treatment regimens for advanced/metastatic non-small-cell lung cancer (NSCLC).

15 Feb 2024

Combination therapy offers breakthrough in NSCLC treatment

A specific combination of targeted therapy and immunotherapy may better help patients with non-small cell lung cancer (NSCLC) overcome inherent immune resistance and reinvigorate anti-tumor activity, according to a new study led by a researcher from The University of Texas MD Anderson Cancer Center.

13 Feb 2024

Persistent presence of SARS-CoV-2 RNA found in long COVID patients

Researchers conduct blood digital transcriptomics to determine the persistence of SARS-CoV-2 RNA in patients with long COVID-19.

23 Jan 2024

Alzheimer's disease found to have five distinct subtypes

Researchers identified five distinct molecular subtypes of Alzheimer's disease using proteomic sequencing, suggesting personalized treatment approaches based on each subtype's unique genetic and pathological characteristics.

10 Jan 2024

New program launched to accelerate access to personalized therapies for children with rare conditions

Today, Wednesday 22 November, the government announced its support for the Rare Therapies Launch Pad, a new programme that will develop a pathway for children with rare conditions to access individualized therapies.

4 Dec 2023

NIH grant to fund development of new gene therapy platform for brain diseases

A two-phase NIH grant will fund research into a new CRISPR-based gene therapy platform that will target genetic brain diseases like Angelman syndrome and H1-4 (HIST1H1E) syndrome.

3 Oct 2023

SARS-CoV-2 infection in coronary vessels linked to cardiovascular complications

Researchers reported that the increased long-term risk of acute cardiovascular complications associated with COVID-19 is linked to SARS-CoV-2 infecting coronary vessels and inducing the formation of plaques.

3 Oct 2023

New study reveals alarming cardiovascular risks from COVID

The study published in Nature Cardiovascular Research reveals that SARS-CoV-2, the virus causing COVID-19, can directly infect coronary vessels and arterial plaques, heightening the risk of cardiovascular complications like heart attacks and strokes. These findings offer critical insights into the increased long-term cardiovascular risks for COVID-19 survivors and open new avenues for targeted therapies.

1 Oct 2023

Key player in ovarian cancer may have implications for PCOS

Researchers explore the involvement and altered expression of BBOX1-AS1 and microRNA-19b in polycystic ovary syndrome.

26 Sep 2023

VAX-seq: the future of mRNA vaccine analysis and quality assurance?

Researchers proposed a simplified approach for analyzing mRNA vaccines using long-read sequencing.

22 Sep 2023

Combination immunotherapy outperforms durvalumab monotherapy in neoadjuvant NSCLC

Combination immunotherapy with the anti-PD-L1 monoclonal antibody durvalumab and other novel agents outperforms durvalumab alone in the neoadjuvant (pre-surgical) setting for early-stage non-small-cell lung cancer (NSCLC), according to researchers at The University of Texas MD Anderson Cancer Center.

14 Sep 2023

Single target, multiple possibilities: microRNA holds promise for epilepsy treatment

Study investigated the role of micro-ribonucleic acid (miRNA) miR-335-5p as a potential therapeutic target for epilepsy.

25 Jul 2023

New porcine model could help develop treatments for Dduchenne muscular dystrophy

The group of LMU scientist Eckhard Wolf has developed a porcine DMD model with a mutation, which mimics the hallmarks of the human disease but develops them in an accelerated mode.

12 Jul 2023

New therapy to mitigate fragile X syndrome may be on the horizon

An antisense therapy developed by Joel D. Richter, PhD, Sneha Shah, PhD, and Jonathan K. Watts, PhD, at UMass Chan Medical School and Elizabeth Berry-Kravis, MD, PhD, at RUSH University Medical Center, restores production of the protein FMRP in cell samples taken from patients with fragile X syndrome.

5 Jul 2023

GREB1 gene key to liver cancer development, study finds

The development of hepatocellular carcinoma, liver cancer, is known to involve abnormal activation of a signaling pathway called Wnt; however, the underlying mechanisms have not been fully understood, until now.

27 Jun 2023